Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 6
2021 8
2022 8
2023 6
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5.
Thottarath S, Gurudas S, Chandak S, Patel PJ, Kotagiri A, Pearce I, McKibbin M, Menon G, Burton BJL, Talks J, Grabowska A, Ghanchi F, Gale R, Karatsai E, Chandra S, Sivaprasad S. Thottarath S, et al. Among authors: gurudas s. Eye (Lond). 2024 May 6. doi: 10.1038/s41433-024-03110-4. Online ahead of print. Eye (Lond). 2024. PMID: 38710939
National prevalence of vision impairment and blindness and associated risk factors in adults aged 40 years and older with known or undiagnosed diabetes: results from the SMART-India cross-sectional study.
Gurudas S, Vasconcelos JC, Prevost AT, Raman R, Rajalakshmi R, Ramasamy K, Mohan V, Rani PK, Das T, Conroy D, Tapp RJ, Sivaprasad S; SMART-India Study Collaborators. Gurudas S, et al. Lancet Glob Health. 2024 May;12(5):e838-e847. doi: 10.1016/S2214-109X(24)00035-4. Epub 2024 Feb 28. Lancet Glob Health. 2024. PMID: 38430915 Free article.
Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3.
Chandra S, Gurudas S, Pearce I, Mckibbin M, Kotagiri A, Menon G, Burton BJL, Talks J, Grabowska A, Ghanchi F, Gale R, Giani A, Chong V, Chen CNT, Nicholson L, Thottarath S, Chandak S, Sivaprasad S. Chandra S, et al. Among authors: gurudas s. Eye (Lond). 2024 May;38(7):1301-1307. doi: 10.1038/s41433-023-02886-1. Epub 2023 Dec 15. Eye (Lond). 2024. PMID: 38102473 Free PMC article.
Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2.
Chandra S, Gurudas S, Burton BJL, Menon G, Pearce I, Mckibbin M, Kotagiri A, Talks J, Grabowska A, Ghanchi F, Gale R, Giani A, Chong V, Yamaguchi TCN, Pal B, Thottarath S, Pakeer RM, Chandak S, Montesel A, Sivaprasad S. Chandra S, et al. Among authors: gurudas s. Eye (Lond). 2024 Mar;38(4):757-765. doi: 10.1038/s41433-023-02769-5. Epub 2023 Oct 18. Eye (Lond). 2024. PMID: 37853106
Study protocol on prevalence of non-exudative macular neovascularisation and its contribution to prediction of exudation in fellow eyes with unilateral exudative AMD (EYE-NEON).
Thottarath S, Chandra S, Gurudas S, Tsai WS, Giani A, De Cock E, Yamaguchi TCN, Sivaprasad S; EYENEON Study Group. Thottarath S, et al. Among authors: gurudas s. Eye (Lond). 2023 Oct;37(14):3004-3008. doi: 10.1038/s41433-023-02460-9. Epub 2023 Mar 7. Eye (Lond). 2023. PMID: 36882530 Free PMC article.
Development and validation of predictive risk models for sight threatening diabetic retinopathy in patients with type 2 diabetes to be applied as triage tools in resource limited settings.
Nugawela MD, Gurudas S, Prevost AT, Mathur R, Robson J, Sathish T, Rafferty JM, Rajalakshmi R, Anjana RM, Jebarani S, Mohan V, Owens DR, Sivaprasad S. Nugawela MD, et al. Among authors: gurudas s. EClinicalMedicine. 2022 Jul 22;51:101578. doi: 10.1016/j.eclinm.2022.101578. eCollection 2022 Sep. EClinicalMedicine. 2022. PMID: 35898318 Free PMC article.
26 results